UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________________________
FORM 8-K
____________________________________
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): January 6, 2015
____________________________________
PharmaCyte Biotech, Inc.
(Exact name of Registrant as Specified in
its Charter)
|
Nevada
(State or Other Jurisdiction of Incorporation)
|
333-68008
(Commission File Number)
|
62-1772151
(IRS Employer Identification No.)
|
12510 Prosperity Drive, Suite 310
Silver Spring, Maryland
(Address of Principal Executive Offices)
(917) 595-2850
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03 Amendments to Articles of
Incorporation or Bylaws
Effective January 6, 2015, Nuvilex, Inc.
(“Company”) changed its legal corporate name to “PharmaCyte Biotech, Inc.” The name change was effected
through a short-form merger pursuant to Section 92A.180 of the Nevada Revised Statutes. A wholly-owned subsidiary of the Company
was merged with and into the Company, with the Company as the surviving entity of the merger. The merger had the effect of amending
the Company’s Certificate of Incorporation to reflect the new legal name of the Company. A copy of the Articles of Merger
effecting the name change, as filed with the Secretary of State of the State of Nevada, is attached hereto as Exhibit 3.1. The
Articles of Merger became effective by their terms on January 6, 2015.
In connection with the name change, the
Company also changed the ticker symbol of its common stock, which previously traded under the ticker symbol “NVLX.”
The Company’s common stock is trading under the ticker symbol “PMCB.”
The merger and resulting name change do
not affect the rights of the Company’s security holders, creditors, customers or suppliers. With the exception of the name
change, there were no changes to the Company’s Certificate of Incorporation or Bylaws.
Item 7.01. Regulation FD Disclosure
On January 7, 2015, the Company issued
a press release announcing the name change, a copy of which is attached hereto as Exhibit 99.1. On January 8, 2015, the Company
issued a press release announcing the new ticker symbol, a copy of which is attached hereto as Exhibit 99.2. The information furnished
in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
Item 9.01 Financial Statements and Exhibits.
|
|
(d) Exhibits.
|
|
|
|
|
|
3.1
|
Articles of Merger merging PharmaCyte Biotech, Inc. with and into Nuvilex, Inc., effective January 6, 2015
|
|
|
99.1
|
Press Release dated January 7, 2015
|
|
|
99.2
|
Press Release dated January 8, 2015
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
PharmaCyte Biotech, Inc.
|
|
|
|
|
|
|
|
|
|
Date: January 9, 2015
|
By:
|
/s/ Kenneth L. Waggoner
|
|
|
|
Kenneth L. Waggoner
Chief Executive Officer, President and General Counsel
|
INDEX TO
EXHIBITS
|
Exhibit
|
|
|
|
Number
|
|
Exhibit Description
|
|
|
|
|
|
3.1
|
|
Articles of Merger merging PharmaCyte Biotech, Inc. with and into Nuvilex, Inc. effective January 6, 2015
|
|
99.1
|
|
Press Release dated January 7, 2015
|
|
99.2
|
|
Press Release dated January 8, 2015
|
Exhibit 3.1
|
ROSS MILLER
Secretary of State
204 North Carson Street, Suite 1
Carson City, Nevada 89701-4520
(775) 684-5708
Website:
www.nvsos.gov
|
Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 1
|
|
USE BLACK INK ONLY - DO NOT
HIGHLIGHT
|
ABOVE SPACE
IS FOR OFFICE USE ONLY
|
Articles
of Merger
(Pursuant
to NRS Chapter 92A)
|
|
1)
|
Name and jurisdiction of organization of each
constituent entity (NRS 92A.200):
|
|
o
|
|
If there are more than four merging entities,
check box and attach an 8 1/2" x 11" blank sheet containing the required information for each additional entity from
article one.
|
|
PharmaCyte Biotech, Inc.
|
|
Name of
merging
entity
|
|
|
Nevada
|
|
Corporation
|
|
Jurisdiction
|
|
Entity type *
|
|
|
|
Name of
merging
entity
|
|
|
|
|
|
|
Jurisdiction
|
|
Entity type *
|
|
|
|
Name of
merging
entity
|
|
|
|
|
|
|
Jurisdiction
|
|
Entity type *
|
|
|
|
Name of
merging
entity
|
|
|
|
|
|
|
Jurisdiction
|
|
Entity type *
|
|
Nuvilex, Inc.
|
|
Name of
surviving
entity
|
|
|
Nevada
|
|
Corporation
|
|
Jurisdiction
|
|
Entity type *
|
* Corporation, non-profit corporation, limited partnership,
limited-liability company or business trust.
Filing Fee: $350.00
|
This form must be accompanied
by appropriate fees.
|
|
Nevada
Secretary of State 92A Merger Page 1
Revised: 8-31-11
|
|
|
ROSS MILLER
Secretary of State
204 North Carson Street, Suite 1
Carson City, Nevada 89701-4520
(775) 684-5708
Website:
www.nvsos.gov
|
Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 2
|
|
USE BLACK INK ONLY - DO NOT
HIGHLIGHT
|
ABOVE SPACE
IS FOR OFFICE USE ONLY
|
|
|
2)
|
Forwarding address where copies of process may be sent by the Secretary of State of Nevada
(if a foreign entity is the survivor in the merger - NRS 92A.190):
|
|
o
|
|
The undersigned declares that a plan of merger has been adopted by each constituent entity (NRS
92A.200).
|
|
x
|
|
The undersigned declares that a plan of merger
has been adopted by the parent domestic entity (NRS 92A.180).
|
|
|
4)
|
Owner's approval (NRS 92A.200) (options a, b or c must be used, as applicable, for each entity):
|
|
o
|
|
If there are more than four merging entities,
check box and attach an 8 1/2" x 11" blank sheet containing the required information for each additional entity from
article one.
|
|
|
|
|
|
(a)
|
|
Owner's approval was not required from
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
|
and, or;
|
|
|
|
|
|
Nuvilex, Inc.
|
|
|
Name of
surviving
entity, if applicable
|
|
* Corporation, non-profit corporation, limited partnership,
limited-liability company or business trust.
|
This form must be accompanied
by appropriate fees.
|
|
Nevada
Secretary of State 92A Merger Page 2
Revised: 8-31-11
|
|
|
ROSS MILLER
Secretary of State
204 North Carson Street, Suite 1
Carson City, Nevada 89701-4520
(775) 684-5708
Website:
www.nvsos.gov
|
Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 3
|
|
USE BLACK INK ONLY - DO NOT
HIGHLIGHT
|
ABOVE SPACE
IS FOR OFFICE USE ONLY
|
|
(b)
|
|
The plan was approved by the required consent
of the owners of *:
|
|
PharmaCyte Biotech, Inc.
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
|
and, or;
|
|
|
|
|
|
|
|
|
Name of
surviving
entity, if applicable
|
|
* Unless otherwise provided in the certificate
of trust or governing instrument of a business trust, a merger must be approved by all the trustees and beneficial owners of each
business trust that is a constituent entity in the merger.
|
This form must be accompanied
by appropriate fees.
|
|
Nevada
Secretary of State 92A Merger Page 3
Revised: 8-31-11
|
|
|
ROSS MILLER
Secretary of State
204 North Carson Street, Suite 1
Carson City, Nevada 89701-4520
(775) 684-5708
Website:
www.nvsos.gov
|
Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 4
|
|
USE BLACK INK ONLY - DO NOT
HIGHLIGHT
|
ABOVE SPACE
IS FOR OFFICE USE ONLY
|
|
(c)
|
|
Approval of plan of merger for Nevada non-profit corporation (NRS 92A.160):
The plan of merger has been approved by
the directors of the corporation and by each public officer or other person whose approval of the plan of merger is required by
the articles of incorporation of the domestic corporation.
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
Name of
merging
entity, if applicable
|
|
|
|
|
|
and, or;
|
|
|
|
|
|
|
|
|
Name of
surviving
entity, if applicable
|
|
|
This form must be accompanied
by appropriate fees.
|
|
Nevada
Secretary of State 92A Merger Page 4
Revised: 8-31-11
|
|
|
ROSS MILLER
Secretary of State
204 North Carson Street, Suite 1
Carson City, Nevada 89701-4520
(775) 684-5708
Website:
www.nvsos.gov
|
Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 5
|
|
USE BLACK INK ONLY - DO NOT
HIGHLIGHT
|
ABOVE SPACE
IS FOR OFFICE USE ONLY
|
|
|
5)
|
Amendments, if any,
to the articles or certificate of the surviving entity. Provide article numbers, if available. (NRS 92A.200)*:
|
Amendment to Article I. - Name of Corporation
The new name of the Corporation shall be: PharmaCyte Biotech, Inc.
|
|
|
6)
|
Location of Plan of
Merger (check a or b):
|
|
x
|
|
(a) The entire plan of merger is attached;
|
|
|
|
|
|
or,
|
|
|
|
o
|
|
(b) The entire plan of merger
is on file at the registered office of the surviving corporation, limited-liability company or business trust, or at the records
office address if a limited partnership, or other place of business of the surviving entity (NRS 92A.200).
|
|
|
7)
|
Effective date and
time of filing: (optional) (must not be later than 90 days after the certificate is filed)
|
* Amended and restated articles may be attached as an
exhibit or integrated into the articles of merger. Please entitle them "Restated" or "Amended and Restated,"
accordingly. The form to accompany restated articles prescribed by the secretary of state must accompany the amended and/or restated
articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent - Nevada parent owning 90% or more of subsidiary), the articles
of merger may not contain amendments to the constituent documents of the surviving entity except that the name of the surviving
entity may be changed.
|
This form must be accompanied
by appropriate fees.
|
|
Nevada
Secretary of State 92A Merger Page 5
Revised: 8-31-11
|
|
|
ROSS MILLER
Secretary of State
204 North Carson Street, Suite 1
Carson City, Nevada 89701-4520
(775) 684-5708
Website:
www.nvsos.gov
|
Articles of Merger
(PURSUANT TO NRS 92A.200)
Page 6
|
|
USE BLACK INK ONLY - DO NOT
HIGHLIGHT
|
ABOVE SPACE
IS FOR OFFICE USE ONLY
|
|
|
8)
|
Signatures - Must
be signed by: An officer of each Nevada corporation; All general partners of each Nevada
limited partnership; All general partners of each Nevada limited-liability limited partnership;
A manager of each Nevada limited-liability company with managers or one member if there
are no managers; A trustee of each Nevada business trust (NRS 92A.230)*
|
|
o
|
|
If there are more than four merging entities,
check box and attach an 8 1/2" x 11" blank sheet containing the required information for each additional entity from
article eight.
|
|
PharmaCyte Biotech, Inc.
|
|
Name of
merging
entity
|
|
|
|
|
|
|
|
/s/
Kenneth L. Waggoner
|
|
Chief Executive Officer
|
|
January 9, 2015
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
Name of
merging
entity
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
Name of
merging
entity
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
Name of
merging
entity
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
Name of
merging
entity
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
and,
|
|
|
|
Nuvilex, Inc.
|
|
Name of
surviving
entity
|
|
|
|
|
|
|
|
/s/ Kenneth L. Waggoner
|
|
Chief Executive Officer
|
|
January 9, 2015
|
|
Signature
|
|
Title
|
|
Date
|
*
The articles of merger must be signed by
each foreign constituent entity in the manner provided by the law governing it (NRS 92A.230). Additional signature blocks may be
added to this page or as an attachment, as needed.
IMPORTANT:
Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied
by appropriate fees.
|
|
Nevada
Secretary of State 92A Merger Page 6
Revised: 8-31-11
|
Agreement of Merger
of
Nuvilex, Inc.
and
PharmaCyte Biotech, Inc.
This Agreement of Merger
(“
Agreement
”) is entered into by and between Nuvilex, Inc., a Nevada corporation (“
Company
”)
and PharmaCyte Biotech, Inc.,
a Nevada corporation, (“
Subsidiary
”) as of January 2, 2015.
WHEREAS the boards
of directors of the Company and Subsidiary have declared it advisable and in the best interests of the corporations and their respective
stockholders to merge Subsidiary with and into Company pursuant Section 92A.180 of the Nevada Revised Statutes (“
NRS
”)
upon the terms and conditions hereinafter set forth.
NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained in this Agreement, the parties agree as follows:
Subsidiary shall, pursuant
to the provisions of the NRS, be merged with and into Company. The Company shall be the surviving corporation from and after the
date on which the articles of merger are filed with the Secretary of State of the State of Nevada (“
Effective Time
”)
and shall change its name, and continue to exist under the name PharmaCyte Biotech, Inc.,
a Nevada corporation (“
Surviving
Corporation
”). The separate existence of Subsidiary shall cease at the Effective Time in accordance with the provisions
of the NRS.
|
|
2.
|
Articles of Incorporation.
|
The Articles of Incorporation
(as amended from time to time, “
Articles of
Incorporation
”) of Company, as now in force
and effect, shall continue to be the Articles of Incorporation of the Surviving Corporation, except that Article First of the Articles
of Incorporation is hereby amended and restated in its entirety as follows:
“The name
of the corporation is PharmaCyte Biotech, Inc.”
and such Articles of
Incorporation as herein amended and changed shall continue in full force and effect until further amended and changed in the manner
prescribed by the provisions of the NRS and the Articles of Incorporation.
The Amended and Restated
Bylaws of Company (“
Bylaws
”), as now in force and effect, shall continue to be the Bylaws of the Surviving Corporation
and shall continue in full force and effect until changed, altered, or amended in the manner prescribed by the provisions of the
NRS and the Bylaws.
|
|
4.
|
Directors and Officers.
|
The directors and officers
of the Company in office at the Effective Time shall be the directors and officers of the Surviving Corporation in office at the
Effective Time, all of whom shall hold their offices until the election and qualification of their respective successors or until
their earlier removal, resignation or death in accordance with the Bylaws of the Surviving Corporation.
|
|
5.
|
Exchange of Capital Stock.
|
At the Effective Time,
each issued and outstanding share of common stock, $0.001 par value per share of Subsidiary shall not be converted or exchanged
in any manner into shares of the Surviving Corporation and shall be cancelled. Each issued and outstanding equity share
of
Company shall not be converted or exchanged in any manner, but as of the Effective Time shall represent equivalent equity shares
of the Surviving Corporation.
|
|
6.
|
Execution, Filing and Recordation.
|
Company and Subsidiary
agree that they will cause to be executed and filed and recorded any document or documents prescribed by the laws of the State
of Nevada, and that they will cause to be performed all necessary acts within the State of Nevada and elsewhere to effectuate the
merger provided for in this Agreement.
This Agreement may
be terminated at any time prior to the Effective Time upon a vote of the directors of either Company or Subsidiary. In the event
of such termination, this Agreement shall forthwith become void and neither party nor their respective officers, directors or stockholders
shall have any liability hereunder.
[The remainder of this page is intentionally
blank]
IN WITNESS WHEREOF,
the undersigned have executed this Agreement of Merger as of the date first written above.
COMPANY:
Nuvilex, Inc.
By:
/s/ Kenneth L. Waggoner
Name:
Kenneth L. Waggoner
Title: Chief Executive Officer, President and General
Counsel
SUBSIDIARY
PharmaCyte Biotech, Inc.
By:
/s/ Kenneth L. Waggoner
Name: Kenneth L. Waggoner
Title: Chief Executive Officer, President and General
Counsel
[
Signature
Page to Short-Form Agreement of Merger
]
Exhibit 99.1
Nuvilex
Announces Name Change to PharmaCyte Biotech
Company’s Shares Will
Trade under New Ticker Symbol PHCB
SILVER
SPRING, MD, January 7, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX) today announced that the Company has changed its
name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the
OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014.
The name change is part of the Company’s transformation process
to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box
®
technology, a proprietary cell encapsulation
platform being utilized to develop “targeted” treatments for solid cancerous tumors and insulin dependent diabetes.
“Over the past year, we’ve
implemented an aggressive strategy to facilitate the advancement of the treatments we are developing for cancer and diabetes, with
our Cell-in-a-Box
®
technology at the core of these treatments. Our new name reflects the tremendous progress we’ve
accomplished in terms of clinical development and signifies the structural completion of our transition to becoming a fully dedicated
biotechnology company,” said Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
Some of the highlights in 2014 that have
marked this transition include:
|
|
·
|
Receiving “orphan drug” designation
from the U.S. Food and Drug Administration (FDA) for the Company’s pancreatic cancer treatment, with applications filed with
the EMA and the TGA for the same status in Europe and Australia.
|
|
|
·
|
Development of a clinical protocol for
a planned Phase 2b clinical trial with the goal of initiating the clinical trial in 2015.
|
|
|
·
|
A preclinical study being completed evaluating
the effectiveness of the Company’s pancreatic cancer treatment on the accumulation of malignant ascites fluid often associated
with the growth of abdominal cancers with positive results that have led to a follow-up study about to be launched.
|
|
|
·
|
The establishment of a world-wide Diabetes
Consortium with a number of research agreements now in place with major universities and institutions that will permit the development
of a break-through treatment for insulin dependent diabetes that combines Cell-in-a-Box
®
with insulin-producing
cells.
|
|
|
·
|
Progression at the University of Northern
Colorado in the pursuit of treatments for brain and other forms of difficult to treat cancers that will combine cannabinoid or
cannabinoid-like compounds with the Cell-in-a-Box
®
technology.
|
“With exciting developments on the
horizon for 2015, our work to develop treatments for both cancer and diabetes will move forward under our new name because it speaks
to what we actually do here at PharmaCyte Biotech,” concluded Mr. Waggoner.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary
cellulose-based live cell encapsulation technology known as Cell-in-a-Box
®
. This unique and patented technology
will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer,
and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer
prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing"
form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the
cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past
clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic
cancer and on treatments for other types of solid cancerous tumors. PharmaCyte Biotech is also developing treatments for cancer
based upon chemical constituents of marijuana known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit
the benefits of Cell-in-a-Box
®
technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing
or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech
the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain
and breast, which affect hundreds of thousands of individuals worldwide every year.
Safe Harbor
This press release may contain forward-looking
statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words
"anticipate," "believe," "estimate," "expect," "intend," "plan" and
similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially
from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays
or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation
or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s
continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More
information about PharmaCyte Biotech can be found at www.PharmaCyteBiotech.com
.
It can also be obtained by contacting Investor Relations.
Investor Relations Contacts:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
jjones@bplifescience.com
Exhibit 99.2
PharmaCyte
Biotech Announces Update on Corporate Changes
Company Trading Under New Ticker
Symbol PMCB
SILVER SPRING, MD, January 8, 2014 (GLOBE NEWSWIRE) –
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer
and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box
®
, today announced that the Company
is trading under its new ticker symbol “PMCB” effective today. It also announced that PharmaCyte Biotech’s CUSIP
number has been changed to 71715X104.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech,
commented, “We have been asked by FINRA to use the ticker symbol “PMCB” rather than the ticker symbol that we
announced yesterday. We are pleased to begin trading under our new corporate name and ticker symbol and look forward to 2015, our
first full year operating solely as a biotechnology firm, with great expectations.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary
cellulose-based live cell encapsulation technology known as Cell-in-a-Box
®
. This unique and patented technology
will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer,
and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer
prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing"
form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the
cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past
clinical trials. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic
cancer and on treatments for other types of solid cancerous tumors. In addition, PharmaCyte Biotech is developing treatments for
cancer based upon chemical constituents of the
Cannabis
plant, known as cannabinoids. In doing so, PharmaCyte Biotech is
examining ways to exploit the benefits of Cell-in-a-Box
®
technology in optimizing the anticancer effectiveness of
cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.
This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such
as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
Safe Harbor
This press release may contain forward-looking
statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words
"anticipate," "believe," "estimate," "expect," "intend," "plan" and
similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially
from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays
or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation
or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s
continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More
information about PharmaCyte Biotech can be found at www.PharmaCyteBiotech.com
.
It can also be obtained by contacting Investor Relations.
Investor Relations Contacts:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
jjones@bplifescience.com